Artificial Pancreas Device Systems (APDS) Markets, 2020-2025: Size & Growth, Segmentation, Regional & Country Breakdowns, Competitive Landscape, Market Shares, Trends and Strategies - ResearchAndMarkets.com

DUBLIN--()--The "Artificial Pancreas Device Systems (APDS) Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

The global artificial pancreas device systems market is currently experiencing robust growth. Looking forward, the market is projected to exhibit a CAGR of around 18% during 2020-2025.

The increasing prevalence of pancreatic cancer, pancreatitis and other chronic ailments is one of the key factors driving the growth of the market. Furthermore, the growing occurrence of diabetes and obesity, due to age-related factors, physical inactivity and unhealthy dietary patterns, is also contributing to the widespread adoption of APDS across the globe.

The rising demand for efficient diabetes monitoring and minimally invasive (MI) drug delivery systems is also providing a boost to the market growth. APDS automatically monitors the glucose levels and administers doses of insulin throughout the day in controlled amounts. Various technological innovations, including the development of software-based wireless systems that are integrated with automated controls, are further contributing to the market growth.

Moreover, regulatory bodies and governments of various nations are significantly investing in research and development (R&D) for the improvement of healthcare infrastructure across the globe. For instance, the Food and Drug Association (US FDA) in the United States is approving an increasing number of new and innovative products, which is creating a positive outlook for the market in the country.

The competitive landscape of the industry has also been examined with some of the key players being Beta Bionics Inc., Bigfoot Biomedical Inc., Cellnovo Limited, Dexcom Inc., Inreda Diabetic B.V., Insulet Corporation, Johnson & Johnson, Medtronic Inc., Roche Holding AG, Tandem Diabetes Care Inc., Typezero Technologies Inc., etc.

Key Questions Answered

  • How has the global artificial pancreas device systems market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What is the breakup of the market based on the device type?
  • What is the breakup of the market based on the treatment type?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global artificial pancreas device systems market and who are the key players?
  • What is the degree of competition in the industry?

Key Topics Covered

1 Preface

2 Scope and Methodology

3 Executive Summary

4 Introduction

4.1 Overview

4.2 Key Industry Trends

5 Global Artificial Pancreas Device Systems Market

5.1 Market Overview

5.2 Market Performance

5.3 Market Forecast

6 Market Breakup by Device Type

6.1 Threshold Suspend Device Systems

6.2 Control-to-Range Systems

6.3 Control-to-Target Systems

7 Market Breakup by Treatment Type

7.1 Bi-hormonal

7.2 Insulin Only

7.3 Hybrid

8 Market Breakup by End-user

8.1 Hospital

8.2 Medical Centres

8.3 Others

9 Market Breakup by Region

9.1 North America

9.2 Asia-Pacific

9.3 Europe

9.4 Latin America

9.5 Middle East and Africa

10 SWOT Analysis

10.1 Overview

10.2 Strengths

10.3 Weaknesses

10.4 Opportunities

10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview

12.2 Bargaining Power of Buyers

12.3 Bargaining Power of Suppliers

12.4 Degree of Competition

12.5 Threat of New Entrants

12.6 Threat of Substitutes

13 Price Indicators

14 Competitive Landscape

14.1 Market Structure

14.2 Key Players

14.3 Profiles of Key Players

14.3.1 Beta Bionics Inc.

14.3.2 Bigfoot Biomedical Inc.

14.3.3 Cellnovo Limited

14.3.4 Dexcom Inc.

14.3.5 Inreda Diabetic B.V.

14.3.6 Insulet Corporation

14.3.7 Johnson & Johnson

14.3.8 Medtronic Inc.

14.3.9 Roche Holding AG

14.3.10 Tandem Diabetes Care Inc.

14.3.11 Typezero Technologies Inc.

For more information about this report visit https://www.researchandmarkets.com/r/hjjhv9

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900